Claims
- 1. A compound of the formula (I): ##STR316## wherein: R.sup.1 is indolyl or benzonfuranyl;
- R.sup.2 is lower alkythio(lower)alkyl or a group of the formula: ##STR317## in which R.sup.5 is hydrogen, lower alkoxy or halogen; R.sup.3 is hydrogen, quinolyl or phenyl which is optionally substituted;
- R.sup.4 is hydrogen or optionally esterified carboxy; and
- X is NR.sup.6,
- in which R.sup.6 is hydrogen, lower alkyl or a group of the formula: ##STR318## in which R.sup.7 is lower alkyl or lower alkoxy, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
- 2. The compound of claim 1, wherein R.sup.3 is quinolyl or phenyl which is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio and halogen.
- 3. The compound of claim 1, wherein R.sup.1 is 2-indolyl or benzofuranyl.
- 4. The compound of claim 1, wherein R.sup.3 is hydrogen.
- 5. The compound of claim 1, wherein R.sup.4 is optionally esterified carboxy.
- 6. The compound of claim 1, which is a solvate.
- 7. The compound of claim 6, which solvate is a hydrate.
- 8. The compound of claim 3, wherein R.sup.1 is benzofuranyl.
- 9. The compound of claim 3, wherein R.sup.1 is 2-indolyl.
- 10. The compound of claim 1, wherein R.sup.6 is hydrogen or methyl.
- 11. The compound of claim 1, wherein R.sup.3 is phenyl, chlorophenyl, bromophenyl, fluorophenyl, ethylphenyl or ethoxyphenyl.
- 12. A pharmaceutical composition, comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in admixture with a pharmaceutically acceptable carrier.
- 13. A method of inhibiting production of nitric oxide in a mammal in need thereof which comprises administering an effective amount of a compound of claim 1 to said mammal.
- 14. The method of claim 13, wherein said mammal is a human.
- 15. A method of treating NO-mediated disease in a mammal, which comprises administering an effective amount of a compound of claim 1, to a mammal is used thereof.
- 16. The method of claim 15, wherein said mammal is a human.
Priority Claims (2)
Number |
Date |
Country |
Kind |
PO0084 |
May 1996 |
AUX |
|
PO4219 |
Dec 1996 |
AUX |
|
Parent Case Info
This application is a 371 of PCT/JP97/01757 filed May 22, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/JP97/01757 |
5/22/1997 |
|
|
5/28/1999 |
5/28/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/45425 |
12/4/1997 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5102901 |
Van Wijngaarden et al. |
Apr 1992 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
9527490 |
Oct 1995 |
WOX |